PTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Sells $36,725.40 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) EVP Lee Scott Golden sold 810 shares of PTC Therapeutics stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $45.34, for a total transaction of $36,725.40. Following the completion of the transaction, the executive vice president now owns 79,849 shares of the company’s stock, valued at $3,620,353.66. The trade was a 1.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

PTC Therapeutics Price Performance

Shares of PTC Therapeutics stock opened at $43.94 on Friday. PTC Therapeutics, Inc. has a 1 year low of $23.58 and a 1 year high of $54.16. The firm has a market cap of $3.39 billion, a PE ratio of -7.40 and a beta of 0.62. The company has a 50 day simple moving average of $45.19 and a two-hundred day simple moving average of $38.44.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on PTCT. StockNews.com downgraded shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Robert W. Baird lifted their target price on shares of PTC Therapeutics from $52.00 to $70.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 3rd. Raymond James began coverage on shares of PTC Therapeutics in a research note on Thursday, October 10th. They issued a “market perform” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $64.00 target price on shares of PTC Therapeutics in a research note on Tuesday, September 17th. Finally, Morgan Stanley raised shares of PTC Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $45.00 to $67.00 in a research note on Friday, December 13th. Three investment analysts have rated the stock with a sell rating, four have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $54.08.

Institutional Investors Weigh In On PTC Therapeutics

A number of hedge funds have recently made changes to their positions in PTCT. KBC Group NV lifted its holdings in shares of PTC Therapeutics by 29.2% in the 3rd quarter. KBC Group NV now owns 2,232 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 504 shares during the last quarter. CWM LLC lifted its holdings in shares of PTC Therapeutics by 354.7% in the 3rd quarter. CWM LLC now owns 2,687 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 2,096 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of PTC Therapeutics by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,782 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 492 shares during the last quarter. Quest Partners LLC bought a new stake in shares of PTC Therapeutics in the 2nd quarter worth approximately $128,000. Finally, Quarry LP lifted its holdings in shares of PTC Therapeutics by 100.0% in the 2nd quarter. Quarry LP now owns 5,000 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 2,500 shares during the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.